Crizanlizumab for Treating COVID-19 Vasculopathy

NCT04435184 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

54

Enrollment

OTHER

Sponsor class

Conditions

COVID-19

Interventions

DRUG: Crizanlizumab
OTHER: 0.9% saline

Sponsor

Johns Hopkins University

Collaborators

[object Object]
[object Object]
[object Object]